- Home
- ASRT vs AVTX Comparison
ASRT vs AVTX Comparison
Compare ASRT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASRT | AVTX |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.1M | 248.3M |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ASRT | AVTX |
|---|---|---|
| Price | $0.73 | $18.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $3.00 | ★ $32.29 |
| AVG Volume (30 Days) | 313.9K | ★ 341.4K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $137,354,000.00 | $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $0.51 | $3.39 |
| 52 Week High | $1.01 | $20.72 |
Technical Indicators
Market Signals| Indicator | ASRT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 53.63 |
| Support Level | $0.75 | $17.18 |
| Resistance Level | $0.80 | $20.20 |
| Average True Range (ATR) | 0.04 | 1.60 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 23.22 | 59.35 |
Price Performance
Historical ComparisonAbout ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).